Recordati Rare Diseases SARL Sustainability Profile
Recordati Rare Diseases SARL, a prominent player in the pharmaceutical industry, is headquartered in France and operates extensively across Europe and beyond. Founded in 2011, the company has rapidly established itself as a leader in the development and commercialisation of innovative treatments for rare diseases, focusing on areas such as metabolic disorders and genetic conditions. With a commitment to improving patient outcomes, Recordati Rare Diseases offers a range of unique therapies that address unmet medical needs. Their core products are distinguished by their efficacy and safety profiles, setting them apart in a competitive market. The company has achieved significant milestones, including strategic partnerships and a growing portfolio of approved therapies, solidifying its position as a trusted name in rare disease management.
DitchCarbon Score
How does Recordati Rare Diseases SARL's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Recordati Rare Diseases SARL's score of 58 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Recordati Rare Diseases SARL, headquartered in France, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Recordati Industria Chimica e Farmaceutica S.p.A., which may influence its climate commitments and performance metrics. As of now, there are no documented reduction targets or climate pledges specific to Recordati Rare Diseases SARL. However, it is important to note that any climate initiatives or targets may be inherited from its parent company, Recordati Industria Chimica e Farmaceutica S.p.A., which operates at a higher corporate level. This cascading of data suggests that the broader corporate strategies and commitments may apply to Recordati Rare Diseases SARL, although specific details are not provided. In summary, while Recordati Rare Diseases SARL does not present its own emissions data or reduction targets, it is part of a corporate family that may have established climate initiatives through its parent organisation. Further information from Recordati Industria Chimica e Farmaceutica S.p.A. would be necessary to gain insights into the overall climate commitments and performance of the group.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 27,785,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 10,302,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 000,000,000 |
How Carbon Intensive is Recordati Rare Diseases SARL's Industry?
How Carbon Intensive is Recordati Rare Diseases SARL's Location?
Recordati Rare Diseases SARL's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 63% of Scope 3 emissions.
Top Scope 3 Categories
Recordati Rare Diseases SARL's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Recordati Rare Diseases SARL has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
